Table 3.
Univariate and multivariate analysis of factors associated with Progression-Free Survival and Overall Survival of all patients.
| Parameters | PFS | OS | ||||
|---|---|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||
| P value | HR (95%CI) | P value | P value | HR (95%CI) | P value | |
| Age≥65 years | 0.272 | 0.682 | ||||
| Gender, male | 0.431 | 0.141 | ||||
| ECOG PS score (>2) | 0.043 | 0.177 | ||||
| ISS Stage | 0.026 | 0.042 | ||||
| LDH>ULN | 0.042 | 0.049 | ||||
| FISHa | 0.001 | 2.911 (1.894-4.473) | <0.001 | <0.001 | 6.820(2.781-16.725) | <0.001 |
| TAMs content>55/hpf | <0.001 | 8.301 (5.019-13.727) | <0.001 | <0.001 | 8.370(3.677-19.054) | <0.001 |
Abbreviations: OS, overall survival; PFS, progression-free survival; HR, hazard ratio; CI, confidence intervals; ECOG PS, Eastern Cooperative Oncology Group performance status;ISS, International Staging System; LDH, lactate dehydrogenase; FISH, interphase fluorescence in situ hybridization;
aPatients with abnormalities of 13q14, 1q21, 14q32 and 17p13 compared with no FISH abnormalities.